Super three notifications, these drugs are not used
2018-07-13
There was no consensus on the purchase of new drugs in tertiary hospitals.
New drug declaration, 4 doorsill
In June 25th, a large 3A hospital in southwest issued the announcement on the receipt of new drug information on the official website. The declaration needs to meet four conditions at the same time. These 4 "thresholds" have blocked some drugs that have passed the conformance evaluation.
First, it belongs to the "Sichuan medicine (vaccine) centralized procurement trading system" platform hanging network varieties.
Second: in accordance with the "Sichuan basic medical insurance, industrial injury insurance and birth insurance drug catalogue (2018 Edition)" related requirements, and submitted to Chengdu medical insurance drug code.
Third: "following" the "Sichuan basic medical insurance, industrial injury insurance and birth insurance drugs catalogue (2018 Edition)", "" the "digestive and Metabolic Drugs", "skin disease drugs", "nervous system drugs", "antitumor drugs and immunomodulators", "antiparasite, insecticide and anthelmintic", Varieties of "respiratory system", "musculoskeletal system drugs" and "sensory drugs".
The policy is lagging behind, and is still blocked by consistency evaluation.
The most important thing is: hospitals have "one product, two regulations" varieties, or with the same level of quality or price of drugs in the hospital, no longer accept declarations.
Specifically, if the product did not win the bid in the last round of bidding, even through the consistency evaluation work, there was no qualification to declare, and the students were stopped at the door of the big three a hospital. It is not surprising that the hospital has such a regulation, because Sichuan has not yet introduced a policy to encourage the purchase and use of drugs through consistent evaluation.
This is a lag to the landing of "the drug centralized purchasing agency should compile the purchasing catalogue according to the generic name of the drug in accordance with the generic name of the drug and promote the equal competition of the generic drugs and the original research drugs" in March this year.
The state requires the adoption of consistent evaluation, the state has also given incentives to use, procurement policies, but the implementation of each province is not synchronized.
The 18 provinces do not move, the country calls you to speed up
The "no move" in Sichuan is not a solitary example. According to statistics, at present, a total of 13 provinces and cities have promulgated the purchase policy for the varieties of the consistent evaluation, and adopt the "special special office" way, such as direct net hanging, and give the biggest policy support through the consistency evaluation, without changing the existing (winning) results.
There are no movements in the 18 provinces.
We need to give a reminder to the provinces that have no action. The meaning of the state is clear: the purpose of imitation is to replace it.
In June 23rd, at the Symposium on "consistency evaluation in action" and high quality generic pharmaceutical advancement, Lai Shiqing, the Ombudsman of the national health and health commission system reform department, pointed out that "we should take a clear-cut stand, and the purpose of imitation is to replace it."
Up to now, the Department of drug administration has issued 4 batches of generic drug consistency evaluation varieties, involving 41 specifications. In this year, more drugs will be evaluated through consistency. Policy delays, or even a certain degree of conflict (some hospitals require the state to negotiate drugs do not account for the proportion of drugs), is not a thorough understanding of the will of the state.
It is also unfair to the pharmaceutical companies that spend tens of millions of yuan to make a consistent evaluation.
